INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Company Overview - Arcturus Therapeutics specializes in creating mRNA vaccines and therapies [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Arcturus, stemming from allegations of providing misleading business information to investors [1] - On October 22, 2025, Arcturus reported Phase 2 trial results for its inhaled mRNA therapy ARCT-032 in cystic fibrosis, which showed no meaningful improvement in lung function (FEV1) [4] - Following the trial results announcement, Arcturus's stock price dropped by 50.17%, closing at $11.54 per share [4]